ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EVG Evgen Pharma Plc

0.875
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.875 0.85 0.90 0.875 0.875 0.88 116,116 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.59 2.39M
Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.88p. Over the last year, Evgen Pharma shares have traded in a share price range of 0.85p to 4.05p.

Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £2.39 million. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.59.

Evgen Pharma Share Discussion Threads

Showing 1001 to 1022 of 13000 messages
Chat Pages: Latest  52  51  50  49  48  47  46  45  44  43  42  41  Older
DateSubjectAuthorDiscuss
19/3/2019
08:19
They already had a price target here starting at something around 100p.So certainly looking good now with the encouraging results coming in.
apfindley
19/3/2019
08:09
The share price here could explode upwards. Everything seems to sound very positive indeed.
soultrading
18/3/2019
11:11
mirako - not necessarily - the whole FDA accelerated approval pathway was set up to use surrogate endpoints eg biomarkers. I'm not sure how that position will change with Gottlieb moving, but I think accelerated approval is a very attractive option for a company like Evgen and they should be looking at it very closely.
supernumerary
18/3/2019
10:43
The primary endpoint in this trial is a biomarker and the FDA will surely want evidence of clinical benefit.
mirako
18/3/2019
10:39
It's clearly the correct thing to do, and as Nobby says, surprising that it wasn't always the case.

I'm also curious about why they seem to be planning to make the current secondary endpoints into the primary endpoints in the next trial. If they get to the next phase it will be because they've succeeded in this one, so why change a winning formula?

supernumerary
18/3/2019
08:51
Encouraging move this morning with about £20k shares bought. Could be an interesting week ahead of the results next week....
nobbygnome
18/3/2019
07:59
Could really take off.
1hopefultrader
18/3/2019
07:57
I guess it makes sense to announce all the SAH results together but I do wonder why they have only realised that now.

Good the breast cancer results are out next week. Hopefully good results will mean that sulforaphane will proceed on to another trial!

nobbygnome
18/3/2019
07:30
got to be in it to win it gl

90p

purple11
18/3/2019
07:29
Evgen Pharma plc

("Evgen Pharma" or "the Company")



Update on SFX-01 trial read-out dates

Final read-out data from Phase II STEM trial expected next week

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the following update on the read-out of its two Phase II trials of SFX-01, the Company's lead development product.

The final read-out of the STEM trial in metastatic breast cancer is expected to be announced early next week, in line with the Company's earlier guidance of Q1 2019.

In the SAS trial of SFX-01 in subarachnoid haemorrhage, the Company is pleased to confirm that the treatment phase of the trial has now concluded with the last patient on the trial having received the final patient dose.

Following advice from clinicians and statisticians, and in the light of commercial considerations, the Company has decided to announce the primary endpoints (safety, tolerability and measures of blood flow in the brain) and secondary endpoints (relating to cognitive function) at the same time, rather than announcing them separately as previously indicated. This approach fully protects the blinded integrity of the secondary endpoint data which continues to be collected post-dosing for six months from the initial haemorrhage.

The SAS trial will therefore remain fully blinded until all of the secondary endpoint data has been collected. The final read-out continues to be expected in late summer 2019.

Steve Franklin, CEO of Evgen Pharma, commented:

"This is a hugely exciting time for Evgen as we build up to the read-out early next week of our Phase II clinical trial of SFX-01 in metastatic breast cancer. These results are expected to be followed in the late summer this year by the final read-out of our SAS Phase II trial of SFX-01 in subarachnoid haemorrhage.

"Following discussions with our clinicians and statistical advisers, we have decided to unblind the SAS trial's primary and secondary endpoint data at the same time. By doing this, we will fully maintain the blinded integrity of the secondary endpoint data, which in this trial are particularly important as they will form the basis of the primary endpoints in subsequent studies. This approach will maximise the commercial value of the dataset from the SAS trial."

purple11
13/3/2019
16:52
jonnybgood4 filtered. His message has been posted on all the biotech threads.

And Firefox warned that the 4d pharma website (in English and Chinese) was insecure.

DYOR etc.

stopstopgo
12/3/2019
12:34
This wait seems even more frustrating as we already know the end points have been met.. or is it just my lack of patience showing through here?
l0ngterm
06/3/2019
19:25
The ceo has said repeatedly let the science do the talking, not the PR team. So investors that look for news will get bored, chase something else etc. Others were expecting a spike or rise into the results. So not really surprised at where we are from a share price perspective.
l0ngterm
06/3/2019
16:33
Only small amounts though - AIM is full of penny profit merchants
dave444
06/3/2019
15:35
so close to gamechanging results and always constant selling..

so irritating.

purple11
05/3/2019
18:00
I must learn how to spell. In my previous post I should of course have said sulforadex.

I have now registered the word "sulphoradex", and will seek compensation from anybody on the BB using it.

stopstopgo
05/3/2019
08:21
Oncology result in next 26 days!
dave444
05/3/2019
07:19
Yes we could get a company coming in or at the very least grant funding through the various NHSE routes
dave444
05/3/2019
07:15
Agree, seems to perform better than market leader. Will it lead to company being taken over I wonder?
ayl30
05/3/2019
07:13
That is positive
dave444
27/2/2019
17:14
If the results in the breast cancer trial are positive the next proposed step is a trial involving combination with Exemestane. I came across the following article;

Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention



As dave444 says we don't have long to wait. If they achieve 20% responders for the six months hopefully the market will view it as a success. However, the response at the interim readout was lukewarm at best.

pdt
27/2/2019
13:46
We will have the result inside the next 32 days according to the RNS!
dave444
Chat Pages: Latest  52  51  50  49  48  47  46  45  44  43  42  41  Older

Your Recent History

Delayed Upgrade Clock